Piper Sandler Maintains Overweight on Eloxx Pharmaceuticals, Lowers Price Target to $1.5

Piper Sandler analyst Edward Tenthoff maintains Eloxx Pharmaceuticals (NASDAQ:ELOX) with a Overweight and lowers the price target from $4 to $1.5.